CO5160272A1 - Combinacion de cerivastatina y fibratos - Google Patents

Combinacion de cerivastatina y fibratos

Info

Publication number
CO5160272A1
CO5160272A1 CO99078829A CO99078829A CO5160272A1 CO 5160272 A1 CO5160272 A1 CO 5160272A1 CO 99078829 A CO99078829 A CO 99078829A CO 99078829 A CO99078829 A CO 99078829A CO 5160272 A1 CO5160272 A1 CO 5160272A1
Authority
CO
Colombia
Prior art keywords
combination
cerivastatin
fibrates
fibrate
combination according
Prior art date
Application number
CO99078829A
Other languages
English (en)
Inventor
Joachim Ippen
Schopen Ulrike
Ziegler Reiner
Schuckler Fritz
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CO5160272A1 publication Critical patent/CO5160272A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

Combinación de cerivastatina con un fibratoCombinación conforme a la reivindicación 1, caracterizada porque el fibrato es fenofibrato o bezafibrato.Medicamento que contenga la combinación conforme a una de las reivindicaciones 1 a 6.1Procedimiento para la fabricación de medicamentos conforme a la reivindicación 8, caracterizado porque el principio activo se mezcla por procedimientos habituales con coadyuvantes farmacéuticos adecuados y la mezcla se incorpora en una formulación adecuada.
CO99078829A 1998-12-18 1999-12-16 Combinacion de cerivastatina y fibratos CO5160272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19858789A DE19858789A1 (de) 1998-12-18 1998-12-18 Kombination von Cerivastatin und Fibraten

Publications (1)

Publication Number Publication Date
CO5160272A1 true CO5160272A1 (es) 2002-05-30

Family

ID=7891784

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99078829A CO5160272A1 (es) 1998-12-18 1999-12-16 Combinacion de cerivastatina y fibratos

Country Status (19)

Country Link
US (1) US6511985B1 (es)
EP (1) EP1140082A1 (es)
KR (1) KR20010093845A (es)
CN (1) CN1330544A (es)
AR (1) AR021643A1 (es)
AU (1) AU3035600A (es)
BR (1) BR9916270A (es)
CA (1) CA2355295A1 (es)
CO (1) CO5160272A1 (es)
DE (1) DE19858789A1 (es)
GT (1) GT199900214A (es)
HN (1) HN1999000208A (es)
IL (1) IL143221A0 (es)
PE (1) PE20001325A1 (es)
PL (1) PL349389A1 (es)
SV (1) SV1999000250A (es)
TR (1) TR200101722T2 (es)
WO (1) WO2000037078A1 (es)
ZA (1) ZA200103918B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001262945B2 (en) 2000-09-20 2006-02-02 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
ATE357216T1 (de) 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
US20050032878A1 (en) 2001-08-07 2005-02-10 Arthur Deboeck Oral pharmaceutical composition containing a combination pparalpha and a hmg-coa reductase inhibitor
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2006084474A2 (en) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20090318496A1 (en) * 2006-08-04 2009-12-24 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2023146320A1 (ko) * 2022-01-28 2023-08-03 동광제약 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (es) 1980-11-19 1986-01-10 Laruelle Claude
WO1988005296A2 (en) 1987-01-27 1988-07-28 Warner-Lambert Company Lpid regulating compositions
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
EP1792616B1 (en) * 1997-07-31 2009-12-16 Abbott Respiratory LLC Composition comprising an HMG-CoA inhibitor and a nicotinic acid compound for treating hyperlipidemia

Also Published As

Publication number Publication date
GT199900214A (es) 2001-06-08
DE19858789A1 (de) 2000-06-21
IL143221A0 (en) 2002-04-21
TR200101722T2 (tr) 2001-11-21
HN1999000208A (es) 2000-11-22
WO2000037078A1 (de) 2000-06-29
CN1330544A (zh) 2002-01-09
SV1999000250A (es) 2000-10-16
PE20001325A1 (es) 2000-12-30
AU3035600A (en) 2000-07-12
BR9916270A (pt) 2001-09-04
PL349389A1 (en) 2002-07-15
US6511985B1 (en) 2003-01-28
KR20010093845A (ko) 2001-10-29
ZA200103918B (en) 2002-05-15
EP1140082A1 (de) 2001-10-10
AR021643A1 (es) 2002-07-31
CA2355295A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
MY118164A (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
RU2000123567A (ru) Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
ES2159591T3 (es) Composicion de liberacion controlada.
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
KR880000092A (ko) 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CL2004000119A1 (es) Composicion farmaceutica que comprende un agonista/antagonista de estrogenos definido y un secretagogo de la hormona del crecimiento, util para tratar una condicion que se presenta con una masa osea reducida.
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
AR022090A1 (es) PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
SE9701161D0 (sv) New use I
ATE339224T1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
AR033403A1 (es) Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida.